Press Releases Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Market Closed - Nasdaq Other stock markets 21:30:01 06/05/2024 BST			5-day change	1st Jan Change
156.9 ^USD	-2.58%		-0.66%	+26.50%

05-06	Sector Update: Health Care Stocks Gain Pre-Bell Monday	MT
05-06	Krystal Biotech Swings to Q1 Profit -- Shares Fall	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Krystal Biotech Announces First Quarter 2024 Financial Results and Provides Business Updates	05-06	AQ
Krystal Biotech to Present at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting	05-02	AQ
Krystal Biotech to Report First Quarter 2024 Financial Results on May 6, 2024	04-26	AQ
Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of Inhaled KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors of the Lung	04-22	AQ
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	04-05	AQ
Krystal Biotech to Present at the American Association for Cancer Research 2024 Annual Meeting	04-04	AQ
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	02-29	AQ
Krystal Biotech to Present at TD Cowen 44th Annual Health Care Conference	02-28	AQ
Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates	02-26	AQ
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	02-21	AQ
Krystal Biotech to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024	02-20	AQ
Cystic Fibrosis Pipeline Insights Report 2024 \| Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, and others.	02-19	AQ
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung	02-13	AQ
Krystal Biotech Announces Publication in the New England Journal of Medicine on the Application of B-VEC to Treat Ocular Complications in Patient with Dystrophic Epidermolysis Bullosa	02-08	AQ
Krystal Biotech to Present at Guggenheim 6th Annual Biotechnology Conference	02-01	AQ
Krystal Biotech Receives Permanent J-code (J3401) for VYJUVEK®	01-04	AQ
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt	12-20	AQ
Krystal Biotech Receives Orphan Drug Designation from the Japanese MHLW for Beremagene Geperpavec-svdt (B-VEC)	12-19	AQ
Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa	11-27	AQ
Krystal Biotech to Present at the Stifel 2023 Healthcare Conference	11-09	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Krystal Biotech, Inc.

Equities

KRYS

US5011471027

Press Releases

Filters